SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

First-in-human results for three investigational inhibitors show anti-tumor activity without unmanageable effects on blood glucose.

The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...

In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...